Genome Edited Tumor Cells as Anti Cancer Vaccines

 This novel vaccine is comprised of inactivated whole tumor cells that lack the CD47 protein, making them more susceptible to immune cells in the body 

 Background: 

The immune system is designed to defend our body against pathogens and dangerous invaders. However, cancer cells possess a plethora of immune evasion mechanisms in reaction to specific immune responses. Harnessing the body's immune system and “teaching” it to fight against cancerous outgrowth has been one of the most rewarding endeavors in cancer therapy. 

 Technology Overview:  

This invention uses human genome editing to convert cancer cells into therapeutic cancer vaccines. The introduction of these genome edited tumor cells into patients will trigger the body’s immune system to recognize and attack cancer cells, leading a significant reduction of cancerous cells. This new cancer therapy could potentially save millions of lives. 

http://binghamton.technologypublisher.com/files/sites/pexels-karolina-grabowska-40471482.jpg

https://www.pexels.com/photo/close-up-view-of-person-holding-a-vaccine-4047148/

 Advantages:  

• It does not require the delivery of antibodies or DNA plasmids to tumors, which is less efficient than this technology usually hard to achieve.
• Genome deletion of CD47 removes the protection of cancer cells from being recognized by macrophages; thus, it elicits much higher level of immunogenicity after administration compared to the use of dead unmodified cancer cells.
• It uses patients' own cells, eliminating the problem of immune rejection.
• It is efficient against metastatic cancer cells.

 Intellectual Property Summary: 

U. S. 16/596,829